Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Andreone

Showing results (131-140 of 189) with videos related to

Pageof 19
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|June 23, 2016
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled studySirio Fiorino, Elisabetta Loggi, Gabriella Verucchi, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Clinical Gastroenterology|February 28, 2013
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatmentPatrick Marcellin, Antonio Craxi, Carlos E Brandao-Mello, et al.
The American Journal of Gastroenterology|July 19, 2008
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosisTommaso Stroffolini, Piero Luigi Almasio, Marcello Persico, et al.
Biomedicines|October 28, 2023
Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case SeriesElisa Bernasconi, Matteo Biagi, Stefania Di Agostino, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Medicine|June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenibAndrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Pageof 19

Showing results (131-140 of 189) with videos related to

Sort By:
Pageof 19
Liver International : Official Journal of the International Association for the Study of the Liver|June 23, 2016
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled studySirio Fiorino, Elisabetta Loggi, Gabriella Verucchi, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Clinical Gastroenterology|February 28, 2013
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatmentPatrick Marcellin, Antonio Craxi, Carlos E Brandao-Mello, et al.
The American Journal of Gastroenterology|July 19, 2008
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosisTommaso Stroffolini, Piero Luigi Almasio, Marcello Persico, et al.
Biomedicines|October 28, 2023
Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case SeriesElisa Bernasconi, Matteo Biagi, Stefania Di Agostino, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Medicine|June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenibAndrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Pageof 19